KISUNLA
As listed in the register: KISUNLA 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
350 mg · concentrado para solución para perfusión
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Donamemab
- Made by
- Eli Lilly Nederland B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Eli Lilly Nederland B.V. |
|---|---|
| Active substance | Donamemab |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 350 mg |
| Form | concentrado para solución para perfusión |
| Classification | N06DX05 · Pain, sleep, mood, epilepsy and the brain |
| Route | vía intravenosa |
| Marketed | Yes, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | KISUNLA 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSION |
| Nº Registro | 1251926001 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.